Evidence map›Paper›PMID 32557376›Full record

ArticleInternational urology and nephrology2020

Hemostatic agent use during partial nephrectomy: trends, outcomes, and associated costs.

Adri M Durant, Erik Lehman, Haley Robyak, Suzanne B Merrill, Matthew G Kaag, Jay D Raman

Abstract read
PubMed Publisher
In one paragraph

Article in International urology and nephrology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Adri M DurantThe Pennsylvania State University, College of Medicine, Hershey, PA, USA.
Erik LehmanDepartment of Public Health Sciences, The Pennsylvania State University, College of Medicine, Hershey, PA, USA.
Haley RobyakThe Pennsylvania State University, College of Medicine, Hershey, PA, USA.
Suzanne B MerrillDepartment of Surgery, Division of Urology, The Pennsylvania State University, College of Medicine, 500 University Drive, H055, Hershey, PA, 17033-0850, USA.
Matthew G KaagDepartment of Surgery, Division of Urology, The Pennsylvania State University, College of Medicine, 500 University Drive, H055, Hershey, PA, 17033-0850, USA.
Jay D RamanDepartment of Surgery, Division of Urology, The Pennsylvania State University, College of Medicine, 500 University Drive, H055, Hershey, PA, 17033-0850, USA. jraman@pennstatehealth.psu.edu.ORCID http://orcid.org/0000-0001-8480-8397
Pennsylvania State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate the ability of hemostatic agents (HA) to limit bleeding complications following partial nephrectomy (PN) and determine HA usage and costs as well as factors associated with post-operative bleeding complications.

methodsThe records of 429 PN performed for kidney cancers were reviewed for clinical, pathologic, and perioperative variables. Surgical approach, HA use, and HA expenditure were determined. Bleeding complications and management to 90 days after PN were annotated. Wilcoxon rank-sum and two-sample t tests identified factors associated with HA use. Univariate and limited multivariate logistic regression determined variables associated with bleeding complications.

resultsUse of HA was associated with longer OR duration, longer ischemia time, higher EBL, and method of PN (OPN and LPN > RPN) (all p values < 0.001). On bivariate analysis, while multiple factors were associated with bleeding complications, neither HA use (p = 0.924) nor the number of HA used (two agents vs one p = 0.712; three agents vs. one p = 0.606) were. A multivariable model noted that increasing RENAL score (p = 0.013) and surgical approach (OPN vs. RPN [p = 0.009] and LPN vs. RPN (p = 0.002]) were independently associated with bleeding complications, while HA use was not (p = 0.294). During the 16 years of analysis, a total of $77,687 USD was spent on HA. Average annual HA expenditure was $4855 USD with the peak being in 2010 where expense was $14,086. Mean annual costs for HA use were greater for OPN vs RAPN starting in 2013 (p = 0.02)

conclusionsThe use of HA during PN was not associated with lower rates of bleeding complications. Therefore, judicious use in a case-specific manner is requisite to limit potentially unnecessary operative cost.

Indexed as

Costs and Cost AnalysisAdultAgedFemaleHemostaticsHumansKidney NeoplasmsMaleMiddle AgedNephrectomyPostoperative HemorrhageRetrospective StudiesHemostaticsComplicationsCostOutcomesPartial nephrectomy

Identifiers

PMID32557376
OpenAlexW3036198477

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.